Korea's improved version of Nexium obtains final approval from US FDA

Published: 2013-08-09 07:00:00

Updated: 2013-08-09 07:00:00

An incrementally modified (IMD) drug developed by a Korean drug company that treats gastro-esophageal reflex disease has received a final approval from the U.S. Food and Drug Administration (FDA) for the first time.

Hanmi Pharmaceutical has won approval from the Food and Drug Administration of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK